Tuesday, June 08, 2021 2:30:27 PM
Mentioned: VBIV
Canada has become a destination for international collaborations and partnerships, as the long-standing reputation for the quality and caliber of research underway in Canadian SMEs, and research institutions drives awareness.
"The annual BIO convention is unique in that unlike other traditional trade shows, it is not companies selling products but rather countries, regions, and states competing to attract companies, talent and investment. This is a difficult competition during ordinary times, but the pandemic has heightened awareness globally of the value of developing domestic biotech innovation capacity. Accordingly, the competition amongst nations to attract ideas, companies and people is even more intense at this year's BIO. Importantly, with Acuitas' technology central to Pfizer's mRNA vaccine and the emergence over the course of the pandemic of AbCellera, Precision Nanosystems, VBI Vaccines, IMV Inc, and Medicago, Canadian companies and technologies have rightly attracted significant global attention. In this context, the BIO convention platform presents an important and timely opportunity to showcase Canadian companies, innovation and talent," commented Andrew Casey President and CEO BIOTECanada.
Canadian programming highlights include the following. Register here.
Wednesday June 910AM ET - Showcasing Canadian Biotechnology Innovation
A time to celebrate the remarkable scientific achievement for which the global biotech industry, the scientific community and regulators should be recognized. Incredible accomplishment of developing vaccines and therapies in extreme circumstances. The discussion will look forward toward the potential of the role the industry is playing during the economic rebuild in keeping Canada at the forefront of the world of biotech discovery, innovation, and entrepreneurship.
Opening chat between Minister Champagne and Andrew Casey.Panel discussion follows, featuring:Dr. Trina Racine, Associate Director, Vaccine Development, VIDODr. Thomas Madden, President and CEO, Acuitas TherapeuticsAdam Buckley, Senior Vice President Business Development, VBI Vaccines Inc
Thursday June 1010AM ET
BIOTECanada in partnership with the Government of Canada present the Canada Cafe featuring presentations by Canada's Trade Commissioner Service. This is an opportunity to enhance Canadian companies' level of knowledge and understanding of the European, North American, and Asian markets followed by a chance to network with Trade Commissioners.
Friday June 1111:00-12:00 PM ET Bio+ech Connec+ featuring Biogen
Bio+ech Connec+ is a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies. This virtual forum will include a plenary session led by senior Biogen representatives who will provide an overview of the company, its R&D priorities including its pipeline and corresponding investment priorities for the period ahead. Biogen representatives will then engage in a question and answer session.
Tuesday June 151:00-2:30 PM ET BIOTECanada, Wilson Sonsini Goodrich & Rosati present the Annual Coast to Coast Competition
Five companies from across Canada will present to a judging panel of key life science investors. The prize is a coveted presentation spot at BIOTECanada's Investor Summit held in Whistler March 2022. There will also be a unique presentation from Caroline Huang, the 2021 National Champion from Sanofi Biogenius Canada showcasing her award-winning project.
PRESENTING COMPANIES JUDGING PANELAxolotl Biosciences (BC) Lee Johnson, WSGRCytophage (MB) Florence Rozen, Le Fonds de Solidarite FTQCSTS Healthcare (ON) Parimal Nathwani, TIAPSoricimed (NB) Elizabeth Douville, AmorChem
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005990/en/
SOURCE: BIOTECanada
Nadine LuntBIOTECanada613-793-6338
Recent VBIV News
- VBI Vaccines Reports Full Year 2023 Financial Results • Business Wire • 04/16/2024 12:00:00 PM
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • Business Wire • 04/11/2024 08:05:00 PM
- VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • Business Wire • 04/09/2024 06:45:00 PM
- VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma • Business Wire • 04/03/2024 12:00:00 PM
- VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform • Business Wire • 04/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:34:40 PM
- VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences • Business Wire • 02/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:23:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:00:27 PM
- VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:07:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:06:26 PM
- VBI Vaccines Reports Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:00:33 PM
- VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program • Business Wire • 10/26/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 11:30:36 AM
- VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern • Business Wire • 09/27/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 12:00:40 PM
- VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM • Business Wire • 09/07/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM